- Home
- PEN
PEN
Penumbra Inc.
as 03-25-2025 9:55am EST
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 11.1B | IPO Year: | 2015 |
| Target Price: | $291.60 | AVG Volume (30 days): | 390.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.36 | EPS Growth: | -84.48 |
| 52 Week Low/High: | $148.00 - $310.00 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,194,615,000 | Revenue Growth: | 12.86% |
| Revenue Growth (this year): | 14.26% | Revenue Growth (next year): | 14.29% |
Stock Insider Trading Activity of Penumbra Inc. (PEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Elsesser Adam | PEN | CEO and President | Mar 19 '25 | Sell | $275.03 | 16,600 | $4,585,137.64 | 43,562 | |
| Elsesser Adam | PEN | CEO and President | Mar 5 '25 | Sell | $283.72 | 61,600 | $17,468,917.42 | 43,562 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Mar 3 '25 | Sell | $287.25 | 600 | $172,458.48 | 66,587 | |
| Bose Arani | PEN | Director | Mar 3 '25 | Sell | $287.36 | 12,000 | $3,448,992.77 | 327,619 | |
| Shiu Lambert | PEN | Chief Accounting Officer | Mar 3 '25 | Sell | $286.08 | 7,789 | $2,225,582.70 | 25,600 | |
| O'Rourke Bridget | PEN | Director | Mar 3 '25 | Sell | $285.48 | 50 | $14,274.00 | 5,573 | |
| Yuen Maggie | PEN | Chief Financial Officer | Mar 3 '25 | Sell | $285.80 | 2,000 | $571,994.90 | 16,103 | |
| Grewal Harpreet | PEN | Director | Jan 3 '25 | Sell | $241.28 | 167 | $40,293.76 | 8,530 | |
| Kassing Don W. | PEN | Director | Jan 2 '25 | Sell | $238.84 | 170 | $40,602.80 | 665 |
Latest Penumbra Inc. News
PEN Breaking Stock News: Dive into PEN Ticker-Specific Updates for Smart Investing
StockStory
a day ago
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q4 Earnings: ICU Medical (NASDAQ:ICUI) Best of the Bunch
Zacks
2 days ago
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues
Simply Wall St.
5 days ago
Do Its Financials Have Any Role To Play In Driving Penumbra, Inc.'s (NYSE:PEN) Stock Up Recently?
Zacks
6 days ago
Penumbra (PEN) Down 8% Since Last Earnings Report: Can It Rebound?
TipRanks
11 days ago
Chipotle upgraded, Charter initiated: Wall Street’s top analyst calls
Argus Research
22 days ago
PEN: Raising target price to $298.00
Investor's Business Daily
22 days ago
Alcon Stock Gets Relative Strength Rating Lift
Zacks
a month ago
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail
Compare PEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PEN Penumbra Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.